Noninvasive Respiratory Assist Devices in the Management of COVID-19-related Hypoxic Respiratory Failure: Pune ISCCM COVID-19 ARDS Study Consortium (PICASo).

OBJECTIVE

To determine whether high-flow nasal oxygen (HFNO) or noninvasive ventilator (NIV) can avoid invasive mechanical ventilation (IMV) in COVID-19-related acute respiratory distress syndrome (ADRS), and the outcome predictors of these modalities.

DESIGN

Multicenter retrospective study conducted in 12 ICUs in Pune, India.

PATIENTS

Patients with COVID-19 pneumonia who had PaO/FiO ratio <150 and were treated with HFNO and/or NIV.

INTERVENTION

HFNO and/or NIV.

MEASUREMENTS

The primary outcome was to assess the need of IMV. Secondary outcomes were death at Day 28 and mortality rates in different treatment groups.

MAIN RESULTS

Among 1,201 patients who met the inclusion criteria, 35.9% (431/1,201) were treated successfully with HFNO and/or NIV and did not require IMV. About 59.5% (714/1,201) patients needed IMV for the failure of HFNO and/or NIV. About 48.3, 61.6, and 63.6% of patients who were treated with HFNO, NIV, or both, respectively, needed IMV. The need of IMV was significantly lower in the HFNO group ( <0.001). The 28-day mortality was 44.9, 59.9, and 59.6% in the patients treated with HFNO, NIV, or both, respectively ( <0.001). On multivariate regression analysis, presence of any comorbidity, SpO <90%, and presence of nonrespiratory organ dysfunction were independent and significant determinants of mortality ( <0.05).

CONCLUSIONS

During COVID-19 pandemic surge, HFNO and/or NIV could successfully avoid IMV in 35.5% individuals with PO/FiO ratio <150. Those who needed IMV due to failure of HFNO or NIV had high (87.5%) mortality.

HOW TO CITE THIS ARTICLE

Jog S, Zirpe K, Dixit S, Godavarthy P, Shahane M, Kadapatti K, Noninvasive Respiratory Assist Devices in the Management of COVID-19-related Hypoxic Respiratory Failure: Pune ISCCM COVID-19 ARDS Study Consortium (PICASo). Indian J Crit Care Med 2022;26(7):791-797.